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Background
Odor identification is a complex process involving different neuronal mechanisms. It is important
from different aspects of quality of life. Postviral neuritis is one of the leading causes of
hyposmia. Attention to it has increased in the last year due to the coronavirus disease 2019
pandemic. Systemic steroids are presumed to benefit such cases through its anti‑inflammatory
mechanism of action. Cinnarizine, being a multimodal mechanism of action drug with a potent
cerebral vasodilator effect, is assumed to have a great potential to be used as adjuvant
treatment to systemic steroids.

Objective

The aim of the study is to assess if there is any role of Cinnarizine as an adjuvant treatment
to steroids in cases of postviral hyposmia.

Patients and methods

This is a single‑blinded, randomized, controlled trial including 82 patients with postviral
hyposmia. Patients were distributed equally into two groups according to the given therapy
with group I receiving 25 mg oral prednisolone per day for 2 weeks along with budesonide
nasal spray/64 µg per puff in a dose of two puffs for each nostril twice daily for 1 month, in
addition to our drug of study Cinnarizine 25 mg given postoperative TDS for 1 month. Group II
received the same but without Cinnarizine. Both groups were compared regarding the number
and percentage of patients having their smell identification test score improved either partially
or fully back to normal.

Results

Cinnarizine intake as an adjuvant treatment to steroids had a significant effect on improving the
smell identification test scores in patients with postviral hyposmia (P˂0.05). However, among
the improved patients in both groups, there was a nonsignificant difference between the two
groups regarding the degree of recovery whether complete or partial (P=0.78).

Conclusion

Cinnarizine has a beneficial effect as an adjuvant treatment to steroids in cases of postviral
hyposmia.
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Introduction
Anosmia or hyposmia, the decreased ability or
inability to detect odors, is estimated to affect 3–20%
of the population [1]. Many causes exist for hyposmia,
including postviral olfactory neuritis, bilateral nasal
obstruction, head traumas, tumors of the brain, uncinate
fits, or neurodegenerative disorders with increasing risk
in the elderly [2].
Hyposmia affects the quality of life in different aspects,
including the detection of food flavor, warning odors
in the vicinity, and social relationships. This provides
a great necessity for the meticulous research regarding
the pathophysiology of hyposmia [3].
Postviral neuritis is one of the leading causes of
hyposmia [4]. Attention to it has increased in last year
due to the coronavirus disease 2019 (COVID‑19)
pandemic. While there is no gold standard of treatment

in postviral hyposmia, many studies have proved that
systemic corticosteroids did help in regaining the sense
of smell in many patients [5–8].
Cinnarizine has a multimodal mechanism of action.
It is a well‑known fact that it has an antihistaminic,
antiserotonergic, and antidopaminergic effects [9]
along with being a good cerebral vasodilator through
its calcium channel blocking effect [10], which is our
primary focus in this particular study. Cinnarizine
belongs to the diphenylmethyl piperazine group [11]. It
inhibits smooth muscle cell contraction in the cerebral
vasculature by blocking L&T‑type voltage‑gated
calcium channel [10]. It also holds to histamine H1
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receptors, muscarinic (acetylcholine) receptors, and
dopamine D2 receptors [9]. Cinnarizine inhibits the
flow of calcium into red blood cells, which increases
the elasticity of the cell wall, thereby increasing their
flexibility and making the blood less viscous [12]. This
allows the blood to travel more efficiently and effectively
through narrowed vessels in order to bring oxygen to
the damaged tissue [12]. It boosts up the brain oxygen
supply [13] and allows for better cerebral perfusion.
The multimodal mechanism of action of Cinnarizine
and its contribution to hyposmia is discussed in detail
later in the discussion section of this article.
This article concerns postviral hyposmia in general.
SARS‑COV‑2 is one of the respiratory tract
viruses that has a higher incidence, in relation to
others, to violate olfactory apparatus. Many articles
discussed the possible mechanism of olfactory loss
in such cases. The majority contributed the olfactory
dysfunction to the violation that occurs to the
integrity of sustentacular cells of olfactory epithelium
with or without accompanying degeneration of
olfactory neurons [14]. Further possible mechanisms
of olfactory loss in cases of postviral hyposmia are
discussed later in this article.
The aim of our study is to assess if there is any role
of Cinnarizine as an adjuvant treatment to steroids in
cases of postviral hyposmia.

Patients and methods
The current study is a single‑blinded, randomized,
controlled clinical trial conducted on recruited patients
from the outpatient clinics of Zulekha Hospital LLC,
Sharjah, UAE, during the period from March, 2019 to
March, 2021. All procedures performed were following
the ethical standards of the Zulekha Hospital Research
Committee and the 1964 Helsinki Declaration and its
later amendments. A written consent was obtained
from every patient before participation in the study.
Our study included 82 adult patients diagnosed
with organic hyposmia following immediately an
upper respiratory tract infection and characterized
by being of sudden onset. Adult patients with an age
range from 18 to 60 years were selected to allow a
broader experience for odor identification and better
cooperation. Patients with a history of posttraumatic
anosmia, having other neurological disorders or
manifestations, with hyposmia/anosmia lasted more
than 6 months, received previous treatment for their
current hyposmia/anosmia, had any contraindications
to any of the used medications or took a prolonged
course of systemic steroid in last 3 months were
excluded from the study.

All patients were assessed by history taking and complete
otorhinolaryngology examination, including endoscopic
nasal examination to exclude any visible intranasal
pathology which may be a cause for the hyposmia.
Computed tomography of the nose and paranasal
sinuses was done for some patients to confirm suspicious
nasal pathology. Any patient confirmed to have chronic
sinonasal pathology was excluded from the study.
The degree of hyposmia was assessed using the
smell identification test with hyposmia graded as
mild (scores of 30–33) in men/scores of 31–34 in
women, moderate (scores of 26–29) in men/scores of
26–30 in women, and severe (scores of 19–25). Anosmia
considered with scores (6–18) while normosmia
considered with scores of more than 33 in men/scores
of more than 34 in women.
Patients got randomly distributed among two equal
groups utilizing the block randomization method.
Group I included 41 patients who received a course
of systemic corticosteroids in the form of 25 mg oral
prednisolone per day for 2 weeks together with local
nasal corticosteroids in the form of budesonide/64 µg
per puff in a dose of two puffs for each nostril twice
daily for 1 month, in addition to our drug of study
Cinnarizine (Stugeron, Janssen Pharmaceuticals
headquartered in Beerse, Belgium and wholly-owned
by Johnson & Johnson.) by Janssen Pharmaceutica
25 mg given postoperative TDS for 1 month. Group II
included 41 patients who received a course of systemic
corticosteroids in the form of 25 mg oral prednisolone per
day for 2 weeks together with local nasal corticosteroids
in the form of budesonide/64 µg per puff in a dose of
two puffs for each nostril twice daily for 1 month.
The author was blinded to the clinical progress of each
patient within both groups as the senior resident, who
is already blinded to the treatment protocol, was invited
to perform the smell identification test for each patient
before and after treatment. Results were collected and
projected to the author at a later stage for statistical
analysis and interpretation of data.
Outcomes

Primary outcomes include comparison between the two
groups regarding the number and percentage of patients
having there smell identification test score improved
either partially or fully back to normosmia. Also, any
possible side effects from the drugs were assessed.

Results
The current study included 82 patients distributed
equally between two groups. Group I included
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41 patients with 27 males and 14 females and an age
of 38.41±12.41 years. Group II included 41 patients
with 32 males and nine females and an age of
39.95±9.61 years. There was a nonsignificant difference
between the two groups regarding age and sex (P=0.58
and 0.22, respectively) (Table 1).
In the current study, there was a nonsignificant
difference between the two groups regarding
the presenting degree of hyposmia and the
presenting duration of hyposmia (P=0.78 and 0.44,
respectively) (Table 2).
In the current study, there was a nonsignificant
difference between the two groups regarding if the
postviral hyposmia was COVID‑19 induced or
not (P=0.44) (Table 3).
In the current study, there was a significant
difference between the two groups regarding
the number and percentage of patients, who had
their smell identification test score improved
posttreatment (P<0.05) favoring group I. However,
among the improved patients in both groups, there
was a nonsignificant difference between the two
groups regarding the degree of recovery whether
complete or partial (P=0.78) (Table 4).
Twenty patients out of 41 patients in group I (48.8%)
experienced minor side effects related to the use of
Cinnarizine in the form of drowsiness and dry mouth,
which did not lead to cessation of treatment. There was
no recorded extrapyramidal side effects of Cinnarizine
use on any of our patients during the study period.
Eighty‑two (100%) patients in both groups experienced
‘to a variable degree’ the common side effects related to
prolonged oral steroid intake and all those symptoms
disappeared after its discontinuation.
Table 1 Demographic data of both study groups
Items

Group I (41)

Group II
(41)

Statistical
test

P

Age (Mean±SD) 38.41±12.41 39.95±9.61 Z=−0.55644 0.57548
Sex [n (%)]
Male
27 (65.9)
32 (78.05) χ2=1.5107 0.219035
Female

14 (34.1)

9 (21.95)

χ2, χ2 test; Z, Z value of Mann–Whitney U test.
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Discussion
All individuals in their lifetime have experienced loss of
smell at some point due to flu, while in most of the cases
the sense of smell returns back to normal gradually; in
few patients there is permanent hyposmia [15,16].
The exact mechanism behind the postviral hyposmia
is no yet clearly understood. Studies have suggested
that there is damage to the layer of mucous membrane
of olfactory epithelium containing olfactory
receptors and neurons in the olfactory bulb that
supplies those receptors. The olfactory epithelium
is a self‑renewing tissue, so any viral pathology that
impairs neuroepithelial regeneration from basal stem
cells may result in olfactory loss [17,18]. Therefore,
basal cells are a logical therapeutic target for particular
olfactory losses. In addition, postviral damage to the
olfactory receptor neurons leads to vasoconstriction of
the olfactory area microcirculation.
Multiple studies done recently in times of COVID‑19
pandemic have come up with some evidence to suggest
a similar mechanism in postviral olfactory hyposmia
caused by COVID‑19, but more studies are required in
this regard for better acceptance of this hypothesis [14].
The present study focusses on the role of Cinnarizine
in postviral olfactory loss restoration based on its
multimodal central mechanism of action. Knowing
its effect for decades in improving cases of inner
ear dysfunction [19] led us to research and study
any similarities in the pathophysiology of inner ear
dysfunction (tinnitus in particular) and hyposmia.
Tinnitus is not a single entity produced by a single cause, it
is a multifactorial phenomenon. The common pathology
is damage and loss of the tiny sensory hair cells in the
cochlea like that of olfactory cells in hyposmia. Tinnitus
also occurs due to vascular insufficiency affecting the
cochlea [20], which has seen also in olfactory area in
cases of hyposmia. Cinnarizine by virtue of being a
potent cerebral and labyrinthine vasodilator improves
blood flow in the inner ear and prevents the constriction
on these vessels and reduces the symptoms of tinnitus.
There are other cerebral vasodilators apart from
Cinnarizine, the effect of which have already been

Table 2 Comparison between the two groups regarding the degree of presenting hyposmia and duration of presenting
hyposmia
Degree of presenting hyposmia [n (%)]
Mild
Moderate
Severe
Duration of presenting hyposmia (days) (mean±SD)
χ2, χ2 test; Z, Z value of Mann–Whitney U test.

Group I (41)

Group II (41)

Statistical test

P

3 (7.3)
20 (48.8)
18 (43.9)

4 (9.7)
17 (41.5)
20 (48.8)

χ2=0.4914

0.782171

43.54±21.88

48±24.17

Z=−0.77438

0.4413
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studied thoroughly in olfactory dysfunction and tinnitus
treatment. Ginkgo biloba extract was one of them. It
increases microperfusion by increasing red blood cell
deformability and decreases whole blood viscosity.
Also it protects mitochondria from oxidative stress and
improves energy metabolism, thus attenuating damage
to cochlear cells, thus reducing the tinnitus [21,22].
Similar mechanism of action of ginkgo biloba extract
has also been found useful in the treatment of hyposmia.
Its cerebral vasodilator and antioxidant effects help in
the restoration of olfactory loss [23,24].
Cinnarizine is known for being a calcium channel
blocker. This led us to study in depth the role of calcium
in olfaction. Calcium plays different roles in the cilia of
olfactory sensory neurons. An increase in intracellular
calcium ions is involved both in odorant‑induced
excitation and adaptation. In the excitation phase there
is odorant‑induced calcium entry into the cilia through
cAMP‑gated channels [25,26]. The role of calcium in
adaptation mainly occurs through a negative feedback
causing the desensitization of cAMP‑gated channels
through calcium ions and calmodulin [27]. The
extrusion of calcium ions from the cilia is caused by
sodium/calcium exchanger that returns the cytoplasmic
calcium ion concentration to basal levels after
stimulation [28]. Therefore, calcium ion concentrations
need to be tightly regulated to allow the olfactory neuron
to convey to the brain a reliable response to odorants
from the external environment [29]. Cinnarizine
neither has a role on cAMP‑gated channels nor on
sodium/calcium exchanger. Cinnarizine, by blocking
L&T‑type voltage‑gated calcium channels, reduces
the calcium influx in the smooth muscles of the
cerebrovascular wall leading to vasorelaxation of the
blood vessels, better red blood cell’s deformability and
improvement in olfactory perfusion. This carries better
Table 3 Comparison between the two groups regarding if the
hyposmia was coronavirus disease 2019 related or not
Items

COVID‑19‑related hyposmia [n (%)]
Yes
23 (56.1)
27 (65.9)
No
13 (31.7)
12 (29.2)
Not sure

P

Group I (41) Group II (41) Statistical test

5 (12.2)

χ2=1.6457

0.439157

2 (4.9)

χ2, χ2 test; COVID‑19, coronavirus disease 2019.

nutrients, better oxygen, and better coadministered
systemic medications (steroids in our scenario) to the
affected olfactory apparatus [12,13].
Cinnarizine has also an antihistaminic effect. The
studies regarding the role of histamine in olfactory
apparatus are very limited. One study by Yu et al. [30]
demonstrated that H1 receptors, H2 receptors, and H3
receptors are strongly expressed in rat olfactory receptor
neurons. Mammalian olfactory receptor neurons
form the primary elements of the olfactory system.
The specific localization of these receptor subtypes in
the olfactory epithelium suggests that histamine may
also play an important role in olfactory transmission.
This role is proven to be inhibitory in insect’s antenna
lobe (which is the functional analog to olfactory bulb in
mammals) [31] and in lobsters [32,33], but still no good
evidence about this inhibitory role in mammals. It was
previously demonstrated that Levocetrizine, a potent
second‑generation H1 antagonist, could improve the
loss of smell in persistent allergic rhinitis, which is not
correlated with improvement in nasal obstruction [34].
This study [30] highlights the presence of histamine
receptors in the olfactory apparatus and also the role
of antihistamines in olfaction improvement either
through blocking the inflammatory effect of histamine
on the olfactory mucosa or blocking the assumed central
inhibitory effect of histamine on the olfactory pathway.
This further supports the role of Cinnarizine in hyposmia.
Cinnarizine has also an antidopaminergic effect. In a
study by Huisman et al. [35], a remarkable increase
in the number of dopaminergic cells in the olfactory
bulbs of Parkinson patients is reported. This is contrary
to what is known about excessive degeneration of
dopaminergic neurons in Parkinson’s disease. Studies
have shown that excessive dopaminergic neurons
degeneration in the pars compacta of substantia nigra
is accompanied by flourished formation in other
areas, one of those areas is the olfactory bulb. This
was evidenced by a significant increase (>100%) of
tyrosine hydroxylase immunoreactive cells there [35].
Because dopamine is known to inhibit olfactory
transmission [8,36–39], this dopamine overdose in
the olfactory bulb may be responsible for the olfactory
dysfunction in Parkinson patients. This study [35]

Table 4 Comparison between the two groups regarding the number and percentage of improved smell identification test score
cases and degree of recovery of hyposmia
Group I (41)
Improvement of smell identification test score [n (%)]
Yes
30 (73.2)
No
11 (26.8)
Degree of recovery of hyposmia [n (%)]
Complete recovery (normosmia)
16 (53.3)
Partial recovery
χ2, χ2 test.

14 (46.7)

Group II (41)

Statistical test

P

21 (51.2)
20 (48.8)

χ2=4.2011

0.040397

12 (57.1)

χ2=0.0724

0.787867

9 (42.9)
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reinforces the inhibitory role of dopamine in olfaction
and the possible benefit of antidopaminergic effect of
Cinnarizine in hyposmia.
So, after thorough evaluation of the multimodal
mechanism of action of Cinnarizine on the olfactory
apparatus and the similarities in pathophysiology
between olfactory dysfunction and tinnitus along with
evaluating the efficiency of other cerebral vasodilators
like ginkgo biloba in the treatment of hyposmia, it can
be very well proposed that Cinnarizine presents itself
as a potential drug which can be used as an additional
treatment in cases of postviral hyposmia.
To the authors’ knowledge there has been no article until
now discussing the value of immediate treatment of early
presented cases of postviral hyposmia compared with the
treatment of lately presented ones, although treatment
protocols are there for immediate interference in sudden
sensorineural hearing loss or sudden facial nerve paralysis,
which are both a cranial nerve disorder, with good evidence
that delayed interference in both disorders depriving
the patient from good chances of recovery. The olfactory
apparatus is the only central nervous element that has the
capability to regenerate throughout life, which explains
why we can still see cases of delayed olfactory recovery [24].
We have faced three limitations in our study, The
first was that we did not get a chance to do a study of
Cinnarizine on the animal model, so we can have a look
on the E/M picture of the animal’s olfactory membrane
pretreatment and posttreatment, which will add a lot to
our knowledge on how this medicament can benefit the
olfactory membrane at a histological level. The second
limitation was that we did not include a third nontreated
control group in our study to eliminate the time healing
factor (spontaneous recovery) on our treated groups. This
was because our Institutional Ethics Committee refused
to deprive any patient included in our study from basic
treatment. The third limitation was that we did not do
a third olfactory assessment with smell identification
test at 6 months posttreatment, so we can detect more
improved cases in both groups, this is because our study
was not funded and the patients had to self‑pay both smell
identification test kits pretreatment and posttreatment.
However, this limitation was somehow beneficial, as the
results of olfactory reassessment 6 months posttreatment
will be greatly affected by the time healing factor on
both groups and we cannot attribute those added
improvements to any of the treatment protocols.

Conclusion
Cinnarizine has a beneficial effect on improving the
smell identification test score of hyposmic patients
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through its multimodal central mechanism of action.
This is considered as a valuable add‑on to steroids
in the treatment of patients suffering from postviral
hyposmia, especially in this challenging time of
worldwide COVID‑19 pandemic where there are
numerous cases of postviral hyposmia left after.
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